Aktie KITE PHARMA INC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Kite Pharma Inc

Aktien

US49803L1098

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Kite Pharma : Gilead Sciences Completes Acquisition of Kite Pharma, Inc.
Kite Pharma : Gilead Sciences Completes Tender Offer for All Outstanding Shares of Kite Pharma, Inc.
Kite Pharma : Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period
Kite Pharma : Companies to Watch as Biotech Makes a Comeback in 2017
BOURSE : Wall Street attendue en hausse à l'ouverture après le passage de Harvey
Gilead Sciences : annonce le rachat de Kite Pharma pour 11,9 milliards de dollars
Kite Pharma : Gilead Sciences to Acquire Kite Pharma for $11.9 Billion
Kite Pharma : Highlights Publication from the National Cancer Institute Demonstrating Responses in Patients with Metastatic Solid Tumors Treated with T Cell Receptor (TCR) Therapy Targeting MAGE A3
Kite Pharma : Reports Second Quarter 2017 Financial Results
Kite Pharma : Submits Investigational New Drug (IND) Application for -585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma
Kite Pharma : Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
Kite Pharma : Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5)
Kite Pharma : to Report Second Quarter 2017 Financial Results on August 8, 2017
Kite Pharma : Announces Initiation of Axicabtagene Ciloleucel CAR-T Clinical Program in the European Union
Kite Pharma : Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD
Kite Pharma : Doses First Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma (ZUMA-5)
Kite Pharma : to Present at August 2017 Investor Conference
Kite Pharma : to Report Second Quarter 2017 Financial Results on August 8, 2017
Kite Pharma : Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel
Kite Pharma : Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Nachrichten Kite Pharma Inc
  5. Andere Sprachen